21. February 2019

Transglutaminases in Translation - Special issue in Analytical Biochemistry



Dear colleagues in academia and industry,

It is our pleasure to announce a special issue in Analytical Biochemistry to appear in Spring of 2020:

“Transglutaminases in Translation – Novel Tools and Methods Impacting on Diagnostics and Therapeutics”


Since the discovery of transglutaminases by H. Waelsch and coworkers in 1957, basic research has created fundamental knowledge regarding this very special class of enzymes, providing the basis for translation to diagnostics and medicine and even to technical applications.

  Auto-antibodies to tissue transglutaminase (TG2) provide a diagnostic standard in celiac disease.
  The first TG2-blocker is currently being evaluated in celiac disease patients in a phase 2a study.
  An anti-TG2 monoclonal antibody for the treatment of a fibrotic kidney injury has just entered phase 1/2 trials.
  Coagulation FXIII is a diagnostic marker in blood coagulation and a target for drug discovery.
  Microbial transglutaminase (MTG), which has been used since the 1990s in the food industry, is now being tested as a component of medical devices.
  Enzymatic conjugation by MTG is a state-of-the-art method for the production of site specifically conjugated antibody drug conjugates with a defined drug-to-antibody ratio.

This special issue of Analytical Biochemistry is dedicated to providing insight into 1) the latest basic research in the field, and 2) research already in translation for diagnostic, therapeutic and technical purposes. The content is anticipated to range from transglutaminase biochemistry, including structural aspects, assays and novel methods, as well as to (patho)physiological roles and pathways. Therapeutic and diagnostic approaches, technical applications in medicinal products and drug manufacturing will also be included in order to provide an up-to-date overview on “Transglutaminases in Translation”. Finally original work, reviews, or a mixture are welcome.

We heartily invite renowned experts in their respective field to contribute to this special issue.

In order to submit a paper for this Special Issue, please sign into the EVISE site for AB via this link:
https://www.evise.com/evise/faces/pages/submission/Submission.jspx?_adf.ctrl-state=182abld8hd_41
Select the drop down menu and choose your Special Issue title “TGases in Translation”. Then choose the article type from the drop down list, add the details and submit your article.

The submissions are open from 1-Aug-2019, and the final submission deadline is 30-Nov-2019
Accepted papers will be published on-line immediately upon acceptance, and summarized in the special edition to be published in early 2020.




We are looking forward to receiving your paper submissions.
Please contact us for any questions.


Best regards,
Ralf Pasternack
Martin Hils
Guest editors for Analytical Biochemistry
Ralf and Martin

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Team-Assistenz (w/m/d) in Teilzeit gesucht
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France

  • European Congress on Thrombosis and Haemostasis

    02.10.2019 - 04.10.2019
    Glasgow, United Kingdom

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA